Sequencing of Agents for Castration-Resistant Prostate Cancer

In this review we will outline an approach to sequencing new therapies for metastatic castration-resistant prostate cancer (CRPC), with particular attention paid to the biology of CRPC.

Genitourinary Cancers

When It Comes to RT for Prostate Cancer, More May Be Better

Anna Azvolinsky, PhD

News | March 07, 2014 | Prostate Cancer, Genitourinary Cancers

By Anna Azvolinsky, PhD

An intense higher-dose radiotherapy regimen may be a better treatment option for men with localized prostate cancer, according to the 10-year results of the international phase III RT01 trial.

FGF Inhibitor No Better Than Sorafenib in Third-Line Metastatic RCC

Leah Lawrence

News | March 03, 2014 | Renal Cell Carcinoma, Genitourinary Cancers, Kidney Cancer

By Leah Lawrence

The FGF inhibitor dovitinib failed to improve progression-free survival outcomes as a third-line treatment for patients with metastatic renal cell carcinoma compared with sorafenib, according to the results of a new study.

RCC Tumors in Obese Patients May Be More Indolent

Leah Lawrence

News | February 19, 2014 | Renal Cell Carcinoma, Genitourinary Cancers, Kidney Cancer

By Leah Lawrence

New research shows that tumors found in obese patients may be more indolent than those in nonobese patients, and this may, in part, be related to alterations in fatty acid metabolism explaining the obesity paradox in clear-cell renal cell carcinoma.

New Biomarkers in Prostate Cancer

E. David Crawford, MD

Karen Ventii, PhD

Neal D. Shore, MD

Review Article | February 15, 2014 | Oncology Journal, Genitourinary Cancers, PSA Screening, Prostate Cancer

By E. David Crawford, MD, Karen Ventii, PhD, and Neal D. Shore, MD

In this article, we review recent advances in the discovery of prostate cancer biomarkers, their integration into clinical practice, and implications for improving clinical management of the disease.

Improving the Early Detection of Prostate Cancer: A Balancing Act

Gerald L. Andriole, MD

John A. Brockman, MD

February 15, 2014 | Oncology Journal, Genitourinary Cancers, PSA Screening, Prostate Cancer

By Gerald L. Andriole, MD and John A. Brockman, MD

Improved early detection of prostate cancer would ideally involve a noninvasive test that allows clinicians to distinguish aggressive cancers from relatively indolent ones. This distinction is especially important given that relatively few men who undergo screening are destined to die of prostate cancer.

Precision Medicine Approaches to the Diagnosis and Management of Prostate Cancer

Eric A. Klein, MD

February 15, 2014 | Oncology Journal, Genitourinary Cancers, PSA Screening, Prostate Cancer

By Eric A. Klein, MD

For those undergoing screening for the presence of previously undiagnosed prostate cancer, the major challenge for new tests is to avoid the overdetection of indolent cancers that limits the clinical utility of the prostate-specific antigen (PSA) test.

Baseline PSA Testing for Men in Their 40s: Currently Available Evidence Strongly Supports Baseline PSA Measurements in This Age Group

William J. Catalona, MD

February 15, 2014 | Oncology Journal, Genitourinary Cancers, PSA Screening, Prostate Cancer

By William J. Catalona, MD

The benefit-to-risk trade-offs associated with PSA screening are highly sensitive to patient preference, underscoring the importance of ensuring that men have the opportunity to decide for themselves whether they wish to have their individual risk for suffering and death from prostate cancer assessed through PSA screening.

Pages

Videos
Podcasts

Recurrence and Relapse in Testicular Cancer
Bruce Roth, MD
August 09, 2013 | Testicular Cancer, Genitourinary Cancers
By Bruce Roth, MD
Dr. Bruce Roth, Siteman Cancer Center, spoke at the 2013 ASCO meeting about topics in seminoma. Here he discusses recurrence, relapse, and seminomatous vs nonseminomatous testicular cancer.
Epidemiology of Seminoma
Bruce Roth, MD
August 09, 2013 | Testicular Cancer, Genitourinary Cancers
By Bruce Roth, MD
Dr. Bruce Roth, Professor of Oncology in the Division of Medicine at Siteman Cancer Center, Washington University at St. Louis, spoke at the 2013 ASCO meeting about topics in seminoma. Here he discusses the epidemiology of seminoma.
Surveillance for Stage I Seminoma: Part II
Bruce Roth, MD
News | August 09, 2013 | Testicular Cancer, Genitourinary Cancers
By Bruce Roth, MD
Dr. Bruce Roth discusses the large Danish study reported at ASCO (abstract 4502) that showed surveillance alone is sufficient after orchiectomy for stage I seminoma, focusing on its impact on post-surgery radiation therapy in this setting.
Surveillance for Stage I Seminoma: Part I
Bruce Roth, MD
August 09, 2013 | Testicular Cancer, Genitourinary Cancers
By Bruce Roth, MD
Dr. Bruce Roth discusses the large Danish study reported at ASCO (abstract 4502) that showed surveillance alone is sufficient after orchiectomy for stage I seminoma.